JP2024102236A5 - - Google Patents

Download PDF

Info

Publication number
JP2024102236A5
JP2024102236A5 JP2024075101A JP2024075101A JP2024102236A5 JP 2024102236 A5 JP2024102236 A5 JP 2024102236A5 JP 2024075101 A JP2024075101 A JP 2024075101A JP 2024075101 A JP2024075101 A JP 2024075101A JP 2024102236 A5 JP2024102236 A5 JP 2024102236A5
Authority
JP
Japan
Prior art keywords
amino
methanone
dihydrofuro
methyl
quinolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024075101A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024102236A (ja
Filing date
Publication date
Priority claimed from JP2023535834A external-priority patent/JP7487421B2/ja
Application filed filed Critical
Publication of JP2024102236A publication Critical patent/JP2024102236A/ja
Publication of JP2024102236A5 publication Critical patent/JP2024102236A5/ja
Pending legal-status Critical Current

Links

JP2024075101A 2020-12-16 2024-05-07 Prmt5阻害剤 Pending JP2024102236A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063126416P 2020-12-16 2020-12-16
US63/126,416 2020-12-16
JP2023535834A JP7487421B2 (ja) 2020-12-16 2021-12-15 Prmt5阻害剤
PCT/US2021/063540 WO2022132914A1 (en) 2020-12-16 2021-12-15 Prmts inhibitors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023535834A Division JP7487421B2 (ja) 2020-12-16 2021-12-15 Prmt5阻害剤

Publications (2)

Publication Number Publication Date
JP2024102236A JP2024102236A (ja) 2024-07-30
JP2024102236A5 true JP2024102236A5 (https=) 2025-01-07

Family

ID=79927288

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023535834A Active JP7487421B2 (ja) 2020-12-16 2021-12-15 Prmt5阻害剤
JP2024075101A Pending JP2024102236A (ja) 2020-12-16 2024-05-07 Prmt5阻害剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2023535834A Active JP7487421B2 (ja) 2020-12-16 2021-12-15 Prmt5阻害剤

Country Status (18)

Country Link
US (2) US11845760B2 (https=)
EP (2) EP4732837A2 (https=)
JP (2) JP7487421B2 (https=)
KR (1) KR20230121820A (https=)
CN (1) CN116888120B (https=)
AR (1) AR124369A1 (https=)
AU (1) AU2021400942A1 (https=)
CA (1) CA3204823A1 (https=)
CL (1) CL2023001738A1 (https=)
CO (1) CO2023008167A2 (https=)
CR (1) CR20230310A (https=)
IL (1) IL303451A (https=)
JO (1) JOP20230138A1 (https=)
MX (1) MX2023007192A (https=)
PE (1) PE20231295A1 (https=)
TW (1) TW202233183A (https=)
UY (1) UY39565A (https=)
WO (1) WO2022132914A1 (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11077101B1 (en) 2018-07-18 2021-08-03 Tango Therapeutics, Inc. Compounds and methods of use
US12403137B2 (en) 2019-10-28 2025-09-02 Tango Therapeutics, Inc. Compounds and methods of use
WO2022026892A1 (en) 2020-07-31 2022-02-03 Tango Therapeutics, Inc. Piperidin-1- yl-n-pyrydi ne-3-yl-2-oxoacet am ide derivatives useful for the treatment of mtap-deficient and/or mt a-accumulating cancers
UY39565A (es) * 2020-12-16 2022-06-30 Amgen Inc Inhibidores de prmt5 novedosos
CA3230199A1 (en) * 2021-08-30 2023-03-09 Amgen Inc. Process for synthesizing naphthyridine derivatives and intermediates thereof
CA3255376A1 (en) * 2022-04-08 2023-10-12 Amgen Inc. CANCER TREATMENTS USING MTA-COOPERATED PRMT5 INHIBITORS
WO2024002263A1 (zh) * 2022-06-30 2024-01-04 南京明德新药研发有限公司 氨基取代的杂芳基衍生物及其应用
EP4549440A4 (en) * 2022-07-01 2026-04-22 Cytosinlab Therapeutics Co Ltd CLASS OF PRMT5 INHIBITORS AND THEIR USES
WO2024021957A1 (zh) * 2022-07-26 2024-02-01 上海和誉生物医药科技有限公司 一种prmt5抑制剂及其制备方法和药学上的应用
KR20250002472A (ko) * 2022-08-03 2025-01-07 아비스코 테라퓨틱스 컴퍼니 리미티드 질소 함유 삼중 축합고리 prmt5 억제제 및 이의 제조 방법 및 약학적 용도
AU2023327684A1 (en) 2022-08-15 2025-03-20 Astrazeneca Ab Mta-cooperative prmt5 inhibitors for use in the treatment of cancer
EP4578862A1 (en) * 2022-08-18 2025-07-02 Medshine Discovery Inc. Amide-containing heterocyclic derivatives and use thereof
CN117658980A (zh) * 2022-09-08 2024-03-08 郑州同源康医药有限公司 双环类prmt5抑制剂
EP4588920A4 (en) * 2022-09-26 2026-01-28 Shanghai Apeiron Therapeutics Company Ltd NEW PRMT5 INHIBITOR AND ITS USE
CN118613482B (zh) * 2022-09-26 2025-09-30 上海湃隆生物科技有限公司 新型prmt5抑制剂及其应用
CN115677708B (zh) * 2022-10-19 2024-11-29 深圳万知达企业管理有限公司 一种吡咯并喹喔啉的制备方法
TW202440126A (zh) * 2022-11-30 2024-10-16 美商安進公司 利用mta協作的prmt5抑制劑和mat2a抑制劑之癌症治療
PE20251883A1 (es) * 2022-12-05 2025-07-22 Amgen Inc Formas solidas de compuestos de naftiridina
CN120418246A (zh) * 2022-12-23 2025-08-01 成都微芯药业有限公司 一类含炔基取代的杂环酰胺衍生物、其制备方法及其应用
CN116332856A (zh) * 2023-01-04 2023-06-27 荟达医药科技(上海)有限公司 一种4-哒嗪甲醇的合成方法
CN118103373A (zh) * 2023-01-18 2024-05-28 上海德琪医药科技有限公司 Prmt5抑制化合物和其用途
WO2024170488A1 (en) 2023-02-13 2024-08-22 Astrazeneca Ab Prmt5 inhibitor for use in cancer therapy
IL322709A (en) * 2023-02-28 2025-10-01 Amgen Inc Process for the synthesis of naphthyridine derivatives and their intermediates
CN121241054A (zh) * 2023-04-14 2025-12-30 北京双鹤润创科技有限公司 氮杂环羰基稠环衍生物及其用途
CR20250446A (es) 2023-04-21 2025-12-02 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos
AU2024264503A1 (en) 2023-04-23 2025-12-04 Suzhou Genhouse Bio Co., Ltd. Amide compound, pharmaceutical composition comprising same, and use thereof
WO2024234821A1 (zh) * 2023-05-17 2024-11-21 四川科伦博泰生物医药股份有限公司 三并环酰胺化合物、包含其的药物组合物及其制备方法和用途
US11845749B1 (en) 2023-07-13 2023-12-19 King Faisal University Substituted pyrido[4′,3′:5,6]pyrazino[1,2-a]indoles as anticancer agents
WO2025016323A1 (zh) 2023-07-14 2025-01-23 江苏亚虹医药科技股份有限公司 蛋白质精氨酸酶甲基转移酶-5抑制剂及其医药用途
WO2025026381A1 (zh) 2023-08-02 2025-02-06 成都微芯药业有限公司 杂环炔基取代的酰胺衍生物、其制备方法及其应用
TW202521525A (zh) 2023-08-09 2025-06-01 大陸商江蘇恆瑞醫藥股份有限公司 雜芳基化合物、其製備方法及其在醫藥上的應用
WO2025039979A1 (zh) 2023-08-18 2025-02-27 江苏亚虹医药科技股份有限公司 蛋白质精氨酸酶甲基转移酶-5抑制剂及其医药用途
WO2025076500A1 (en) * 2023-10-06 2025-04-10 Amgen Inc. Cancer treatments using mta-cooperative prmt5 inhibitors
WO2025077856A1 (en) * 2023-10-12 2025-04-17 Beijing Double-Crane Runchuang Technology Co., Ltd. Tricyclic-carbonyl-nitrogen heterocyclic derivatives and use thereof
TW202519223A (zh) * 2023-10-31 2025-05-16 大陸商康百達(四川)生物醫藥科技有限公司 一種吡啶衍生物及其在醫藥上的應用
US20250154172A1 (en) * 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
CN119751486B (zh) * 2023-12-29 2025-11-21 赛岚(杭州)生物医药科技有限公司 一类prmt5抑制剂及其用途
WO2025166229A1 (en) * 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Tricyclic amidino compounds as prmt5 inhibitors
WO2025166274A1 (en) * 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Tricyclic guanidino compounds as prmt5 inhibitors
WO2025166215A1 (en) * 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Triheterocyclic guanidino compounds as prmt5 inhibitors
WO2025176054A1 (zh) * 2024-02-20 2025-08-28 华润医药研究院(深圳)有限公司 三环杂环类化合物及其制备方法和医药用途
TW202602453A (zh) * 2024-03-14 2026-01-16 智擎生技製藥股份有限公司 Mta協同性的prmt5抑制劑
WO2025209511A1 (zh) * 2024-04-03 2025-10-09 华润医药研究院(深圳)有限公司 杂环类化合物及其制备方法和医药用途
WO2025215153A1 (en) * 2024-04-10 2025-10-16 Ryvu Therapeutics S.A. Prmt5 inhibitors
WO2025218671A1 (en) * 2024-04-16 2025-10-23 Shanghai Apeiron Therapeutics Company Limited Novel prmt5 proteolysis targeting chimeric molecules and associated methods of use
WO2025257104A1 (en) 2024-06-10 2025-12-18 Sandvik Mining And Construction Tools Ab Diamond and cemented carbide composite material
WO2025265110A1 (en) 2024-06-21 2025-12-26 Amgen Inc. Oral pharmaceutical compositions comprising a naphthyridine compound
CN119552167B (zh) * 2025-01-24 2026-02-03 赛岚(杭州)生物医药科技有限公司 一类用于抑制prmt5的化合物及其药物组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2703851T3 (es) 2014-08-22 2019-03-12 Merck Patent Gmbh Indazoles
EP3939986A1 (en) * 2017-08-09 2022-01-19 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
US12552826B2 (en) * 2018-08-07 2026-02-17 Merck Sharp & Dohme Llc PRMT5 inhibitors
EP3833668B1 (en) * 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2021163344A1 (en) * 2020-02-12 2021-08-19 Amgen Inc. Novel prmt5 inhibitors
UY39565A (es) * 2020-12-16 2022-06-30 Amgen Inc Inhibidores de prmt5 novedosos

Similar Documents

Publication Publication Date Title
JP2024102236A5 (https=)
JP7487421B2 (ja) Prmt5阻害剤
US11964961B2 (en) Heteroaromatic compounds and their use as dopamine D1 ligands
EP4598916A1 (en) Heterocyclic inhibitors of kras g12c mutant proteins and uses thereof
KR20210091954A (ko) 피리도[3,4-d]피리미딘 유도체 및 이를 포함하는 치료용 약학 조성물
TWI325865B (en) Pyrazolopyridine derivatives
JP6162144B2 (ja) 4,4−二置換−1,4−ジヒドロピリミジン、及びb型肝炎の処置のための医薬としてのその使用
JP2025535045A (ja) Kras g12c変異タンパク質の複素環阻害剤及びその使用
CN113874363A (zh) 蛋白质酪氨酸磷酸酶抑制剂
IL256964A (en) Csf-1r receptor antagonists
JP2013523884A5 (https=)
CN114945571A (zh) 环状化合物及其使用方法
CA3202212A1 (en) Indole derivatives useful in treating conditions associated with cgas
TW200817375A (en) Compounds and compositions as ITPKB inhibitors
JP2024528021A (ja) 新規なparp7阻害剤及びその使用
TW201113286A (en) Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors
JP2022539604A5 (https=)
JP7681116B2 (ja) カルボニル置換ジアザスピロ化合物及びその使用
JP2020531487A5 (https=)
WO2015028848A1 (en) Bicyclic heterocyclic compounds as multi-kinase inhibitors
WO2025132946A1 (en) Phenylpyrrolidine derivatives and their use as poi-theta derivatives
WO2025255288A1 (en) Pkc-theta inhibitors, compositions, and methods of use
KR20230107542A (ko) 헤테로방향족 화합물 및 이의 용도
US20260125364A1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands
CN105461709A (zh) 取代脲衍生物及其在药物中的应用